| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2aa388e460f6cf478bd46c925c6ab10e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate |
2017-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c21245c9b7ad5e0e697c4fb12257e61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f387c79a0591081cc4e597fb59abddcd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_089dc372d863f986167c5fcae7697445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7378835ef5b934cc70b2a8c29948054e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6aeebbb80fbbab11f1428cbabeb7477 |
| publicationDate |
2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020163962-A1 |
| titleOfInvention |
Pharmaceutical composition of nilotinib |
| abstract |
A method of treating leukaemia comprising orally administering to a patient in need thereof reduced daily doses of nilotinib of 100 mg to 600 mg, wherein the nilotinib is administered in a dosage form having a composition comprising nilotinib butanedisulphonate (2:1) or nilotinib butanedisulphonate (1:1). |
| priorityDate |
2016-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |